Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial

Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal antibody approved in several countries for the add-on maintenance treatment of patients with severe eosinophilic asthma aged 12 years and older. In the 28-week Phase III ZONDA trial (ClinicalTrials.gov identifier: NCT02075255)...

Full description

Bibliographic Details
Main Authors: Andrew Menzies-Gow, Jonathan Corren, Elisabeth H. Bel, Jorge Maspero, Liam G. Heaney, Mark Gurnell, Peter Wessman, Ubaldo J. Martin, Shahid Siddiqui, Esther Garcia Gil
Format: Article
Language:English
Published: European Respiratory Society 2019-09-01
Series:ERJ Open Research
Online Access:http://openres.ersjournals.com/content/5/3/00009-2019.full

Internet

http://openres.ersjournals.com/content/5/3/00009-2019.full

Similar Items